Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) clinical trials

A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.

This study is testing a new vaccine for RSV infection in adults aged 18-49 who are at higher risk. It compares how well their immune system responds to the vaccine to how older adults (60+) respond, and checks for any side effects.